FAS Gene Mutation in a Case of Autoimmune Lymphoproliferative Syndrome Type IA With Accumulation of γδ+ T Cells

2003 ◽  
Vol 27 (4) ◽  
pp. 546-553 ◽  
Author(s):  
Anke van den Berg ◽  
Rienk Tamminga ◽  
Debora de Jong ◽  
Ewerton Maggio ◽  
Willem Kamps ◽  
...  
Blood ◽  
2001 ◽  
Vol 98 (8) ◽  
pp. 2466-2473 ◽  
Author(s):  
Jack J. H. Bleesing ◽  
Margaret R. Brown ◽  
Stephen E. Straus ◽  
Janet K. Dale ◽  
Richard M. Siegel ◽  
...  

Abstract Autoimmune lymphoproliferative syndrome (ALPS) type Ia is caused by inherited defects in apoptosis and is characterized by nonmalignant lymphoaccumulation, autoimmunity, and increased α/β+ double-negative T cells (α/β+-DNT cells). This study reports immunophenotypic findings in 166 members of 31 families with ALPS type Ia, associated with genetic mutations in theTNFRSF6 gene encoding Fas. The ALPS type Ia probands (n = 31) and relatives having both a Fas mutation and clinically proven ALPS (n = 28) showed significant expansion of CD8+T cells, α/β+-DNT cells, γ/δ+-DNT cells, CD3+/ HLA-DR+ T cells, CD8+/CD57+ T cells, and CD5+ B cells. Relatives with Fas mutations, but without all the required criteria for ALPS (n = 42), had expansions of CD8+ T cells, α/β+-DNT cells, and γ/δ+-DNT cells. Interestingly, relatives without a Fas mutation and with no features of ALPS (n = 65) demonstrated a small but significant expansion of CD8+ T cells, both DNT cell subsets, and CD5+ B cells. As compared to unrelated healthy controls, lymphocyte subset alterations were greatest in the probands, followed by the relatives with mutations and ALPS. Probands and relatives with mutations and ALPS also showed a lower number of CD4+/CD25+ T cells that, in combination with an independent increase in HLA-DR+ T cells, provided a profile predictive of the presence of clinical ALPS. Because quantitative defects in apoptosis were similar in mutation-positive relatives regardless of the presence of clinical ALPS, factors, other than modifiers of the Fas apoptosis pathway, leading to these distinctive immunophenotypic profiles most likely contribute to disease penetrance in ALPS.


2005 ◽  
Vol 202 (10) ◽  
pp. 1341-1348 ◽  
Author(s):  
Lin Liu ◽  
Elise Tran ◽  
Yani Zhao ◽  
Yuchen Huang ◽  
Richard Flavell ◽  
...  

The number of effector T cells is controlled by proliferation and programmed cell death. Loss of these controls on self-destructive effector T cells may precipitate autoimmunity. Here, we show that two members of the growth arrest and DNA damage-inducible (Gadd45) family, β and γ, are critical in the development of pathogenic effector T cells. CD4+ T cells lacking Gadd45β can rapidly expand and invade the central nervous system in response to myelin immunization, provoking an exacerbated and prolonged autoimmune encephalomyelitis in mice. Importantly, mice with compound deficiency in Gadd45β and Gadd45γ spontaneously developed signs of autoimmune lymphoproliferative syndrome and systemic lupus erythematosus. Our findings therefore identify the Gadd45β/Gadd45γ-mediated control of effector autoimmune lymphocytes as an attractive novel target for autoimmune disease therapy.


Blood ◽  
2001 ◽  
Vol 97 (10) ◽  
pp. 3161-3170 ◽  
Author(s):  
Uri Lopatin ◽  
Xu Yao ◽  
Richard K. Williams ◽  
Jack J. H. Bleesing ◽  
Janet K. Dale ◽  
...  

Abstract Autoimmune lymphoproliferative syndrome (ALPS) is an inherited disorder in which genetic defects in proteins that mediate lymphocyte apoptosis, most often Fas, are associated with enlargement of lymph nodes and the spleen and a variety of autoimmune manifestations. Some patients with ALPS have relatives with these same apoptotic defects, however, who are clinically well. This study showed that the circulating levels of interleukin 10 (IL-10) were significantly higher (P < .001) in 21 patients with ALPS than in healthy controls. Moreover, the peripheral blood mononuclear cells (PBMCs) and lymphoid tissues of these patients with ALPS contained significantly higher levels of IL-10 messenger RNA (mRNA;P < .001 and P < .01, respectively). By fractionating PBMC populations, disproportionately high concentrations of IL-10 mRNA were found in the CD4−CD8−T-cell population, expansion of which is virtually pathognomonic for ALPS. Immunohistochemical staining showed intense IL-10 protein signals in lymph node regions known to contain CD4−CD8− T cells. Nonetheless, in vitro studies showed no influence of IL-10 on the survival of CD4−CD8− T cells. Overexpression of IL-10 in patients with inherited apoptotic defects is strongly associated with the overt manifestations of ALPS.


2001 ◽  
Vol 41 (5-6) ◽  
pp. 501-511 ◽  
Author(s):  
Jutte van Derwerff Ten Bosch ◽  
Jacques Otten ◽  
Kris Thielemans

Immunobiology ◽  
2007 ◽  
Vol 212 (2) ◽  
pp. 73-83 ◽  
Author(s):  
Manuel J. Del-Rey ◽  
Javier Manzanares ◽  
Alberto Bosque ◽  
Juan I. Aguiló ◽  
José Gómez-Rial ◽  
...  

2019 ◽  
Vol 143 (1) ◽  
pp. 421-424.e11 ◽  
Author(s):  
Akihiro Hoshino ◽  
Xi Yang ◽  
Kay Tanita ◽  
Kenichi Yoshida ◽  
Toshiaki Ono ◽  
...  

2019 ◽  
Vol 144 (2) ◽  
pp. 245-251
Author(s):  
Daniel R. Matson ◽  
David T. Yang

Autoimmune lymphoproliferative syndrome (ALPS) is an inherited nonmalignant lymphoproliferative disorder characterized by heterozygous mutations within the first apoptosis signal receptor (FAS) signaling pathway. Defects in FAS-mediated apoptosis cause an expansion and accumulation of autoreactive CD4− and CD8− (double-negative) T cells, leading to cytopenias, splenomegaly, lymphadenopathy, autoimmune disorders, and a greatly increased lifetime risk of lymphoma. The differential diagnosis of ALPS includes infection, other inherited immunodeficiency disorders, primary and secondary autoimmune syndromes, and lymphoma. The most consistent pathologic feature is a florid paracortical expansion of double-negative T cells in lymph nodes. A presumptive clinical diagnosis can be made from symptoms and a constellation of laboratory test results. However, a definitive diagnosis requires ancillary testing and enables disease subclassification. Recognition of ALPS is critical, as treatment with immunosuppressive therapies can effectively reduce or ameliorate symptoms for most patients.


Sign in / Sign up

Export Citation Format

Share Document